Junicedric acidCAS# 41787-69-3 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 41787-69-3 | SDF | Download SDF |
| PubChem ID | 38347252 | Appearance | Powder |
| Formula | C20H32O4 | M.Wt | 336.46 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (1S,4aR,5S,8aR)-5-[(3S)-4-carboxy-3-methylbutyl]-1,4a-dimethyl-6-methylidene-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid | ||
| SMILES | CC(CCC1C(=C)CCC2C1(CCCC2(C)C(=O)O)C)CC(=O)O | ||
| Standard InChIKey | HPQKNJHVWUWAOR-BWCMQUJESA-N | ||
| Standard InChI | InChI=1S/C20H32O4/c1-13(12-17(21)22)6-8-15-14(2)7-9-16-19(15,3)10-5-11-20(16,4)18(23)24/h13,15-16H,2,5-12H2,1,3-4H3,(H,21,22)(H,23,24)/t13-,15-,16+,19+,20-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Junicedric acid has gastroprotective effects. |
Junicedric acid Dilution Calculator
Junicedric acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9721 mL | 14.8606 mL | 29.7212 mL | 59.4424 mL | 74.303 mL |
| 5 mM | 0.5944 mL | 2.9721 mL | 5.9442 mL | 11.8885 mL | 14.8606 mL |
| 10 mM | 0.2972 mL | 1.4861 mL | 2.9721 mL | 5.9442 mL | 7.4303 mL |
| 50 mM | 0.0594 mL | 0.2972 mL | 0.5944 mL | 1.1888 mL | 1.4861 mL |
| 100 mM | 0.0297 mL | 0.1486 mL | 0.2972 mL | 0.5944 mL | 0.743 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Hypecorinine
Catalog No.:BCN3298
CAS No.:41787-57-9
- H-Leu-pNA.HCl
Catalog No.:BCC2972
CAS No.:4178-93-2
- Lenvatinib (E7080)
Catalog No.:BCC1172
CAS No.:417716-92-8
- 14-Deoxyandrographolide
Catalog No.:BCN3706
CAS No.:4176-97-0
- ar-Curcumene
Catalog No.:BCN7534
CAS No.:4176-06-1
- Evonimine
Catalog No.:BCN3082
CAS No.:41758-69-4
- Dihydrophaseic acid
Catalog No.:BCN5478
CAS No.:41756-77-8
- Ophiopogonin D
Catalog No.:BCN5004
CAS No.:41753-55-3
- Ginsenoside Rb1
Catalog No.:BCN1063
CAS No.:41753-43-9
- Acuminatin
Catalog No.:BCN5477
CAS No.:41744-39-2
- (-)-Sativan
Catalog No.:BCN7752
CAS No.:41743-86-6
- Irisflorentin
Catalog No.:BCN1278
CAS No.:41743-73-1
- Hesperetin-7-methyl ether
Catalog No.:BCN8501
CAS No.:
- Mangiferolic acid
Catalog No.:BCN4636
CAS No.:4184-34-3
- Alatamine
Catalog No.:BCN3100
CAS No.:41855-33-8
- Bezafibrate
Catalog No.:BCC4639
CAS No.:41859-67-0
- 2,3-DCPE hydrochloride
Catalog No.:BCC2384
CAS No.:418788-90-6
- PYR-41
Catalog No.:BCC4470
CAS No.:418805-02-4
- Nitrocefin
Catalog No.:BCC6544
CAS No.:41906-86-9
- Isopropyl 4-Hydroxybenzoate
Catalog No.:BCN8409
CAS No.:4191-73-5
- Trilobatin
Catalog No.:BCN5479
CAS No.:4192-90-9
- N1-Methyl-4-nitrobenzene-1,2-diamine
Catalog No.:BCC9070
CAS No.:41939-61-1
- MLR 1023
Catalog No.:BCC6232
CAS No.:41964-07-2
- Pinocembrin chalcone
Catalog No.:BCN7223
CAS No.:4197-97-1
Synthesis and pharmacological activity of diterpenylnaphthoquinone derivatives.[Pubmed:21996716]
Molecules. 2011 Oct 13;16(10):8614-28.
New diterpenylquinones, combining a diterpene diacid and a naphthoquinone, were prepared from Junicedric acid and lapachol. The new derivatives were assessed as gastroprotective agents by the HCl-EtOH-induced gastric lesions model in mice as well as for basal cytotoxicity on the following human cell lines: Normal lung fibroblasts (MRC-5), gastric epithelial adenocarcinoma (AGS), and hepatocellular carcinoma (Hep G2). Several of the new compounds were significantly active as antiulcer agents and showed selective cytotoxicity against AGS cells.
Synthesis, gastroprotective effect and cytotoxicity of new amino acid diterpene monoamides and diamides.[Pubmed:20966879]
Molecules. 2010 Oct 21;15(10):7378-94.
Following our studies on the gastroprotective effect and cytotoxicity of terpene derivatives, new amides were prepared from the diterpene 8(17)-labden-15,19-dioic acid (Junicedric acid) and its 8(9)-en isomer with C-protected amino acids (amino acid esters). The new compounds were evaluated for their gastroprotective effect in the ethanol/HCl-induced gastric lesions model in mice, as well as for cytotoxicity using the following human cell lines: normal lung fibroblasts (MRC-5), gastric adenocarcinoma cells (AGS) and liver hepatocellular carcinoma (Hep G2). A dose-response experiment showed that at 25 mg/kg the C-15 leucyl and C-15,19-dileucylester amides of Junicedric acid reduced gastric lesions by about 65.6 and 49.6%, respectively, with an effect comparable to lansoprazole at 20 mg/kg (79.3% lesion reduction). The comparison of the gastroprotective effect of 18 new amino acid ester amides was carried out at a single oral dose of 25 mg/kg. Several compounds presented a strong gastroprotective effect, reducing gastric lesions in the 70.9-87.8% range. The diprolyl derivative of Junicedric acid, the most active product of this study (87.8% lesion reduction at 25 mg/kg) presented a cytotoxicity value comparable with that of the reference compound lansoprazole. The structure-activity relationships are discussed.
